Steven Goldman, MD

Professor of Medicine

Additional Contact Info: 

Fax:  (520) 629-4636

Education: 
1960-1964 Cornell University, B.A.
1964-1968 University of Cincinnati Medical School, M.D.
Honors and Awards: 

UA Charles W. Hall, Jr. Memorial Cardiology Fellowship Teaching Award, 2010
Founders Day Speaker, University of Arizona College of Medicine - Tucson, 2008

Major Areas of Research Interest: 

Dr. Goldman’s clinical research has focused on graft patency (evaluating the openness of arteries) after coronary artery bypass grafting (CABG). He has been the principle investigator and co-investigator on a number of large VA multicenter studies that defined the appropriate use of aspirin for vein graft patency after CABG.  He is currently completing a long-term trial defining radial artery graft patency after CABG.

Dr. Goldman’s work in the laboratory focuses on cardiovascular physiology and pharmacology. To this end, he has been investigating cell-based therapy for heart failure using stem cells seeded on a biodegradable patch as treatment for heart failure. He and Jordan Lancaster, PhD, founded Avery Therapeutics, a biotechnology start-up company that is a spin off from the University of Arizona to commercialize this idea.

Sponsored Research Through MSRP: 

Susan Shaw (MSRP 1982): "Control of the Peripheral Circulation in Hypertensive Dogs and Cats" 

Melissa Denn (MSRP 2011): "Molecular Analysis of Progenitor Cell Activity and Phenotype after Fibroblast Patch Implantation to Infarcted Tissue in Heart Failure"

Pablo Sanchez (MSRP 2014): "iPSC-Derived Cardiomyocycte Scaffold on Diastolic Function in Rats with Chronic Heart Failure" 

Chelsea Takamatsu (MSRP 2017): "Immune Response to Bioengineered Human-Induced Pluripotent Stem Cell-Derived Cardiomyocyte Patch to Treat Heart Failure"

Selected Publications: 

Weigand K, Witte R, Moukabary T, Lancaster J, Chinyere I, Pierce MK, Goldman S. Juneman E.  In-Vivo Electrophysiological Studies in Rat Model of Chronic Ischemic Heart Failure IEEE Biomedical Transactions 2017; 64:6; 1393-1399DOI: 10.1109/TBME.2016.2605578.

Green JB, Bethel A, Armstrong PW et al., for the TECOS Study Group (S Goldman).  (2015).  Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.  N Engl J Med 2015; 373:232-242July 16, 2015DOI: 10.1056/NEJMoa1501352

Hayward RA, Reaven PD, Wiitala WL, Bahn GD, Reda DJ, Ge L, McCarren M, Duckworth WC, and Emanuele NV for the VADT Investigators (S Goldman). (2015) Follow-up of Glycemic Control and Cardiovascular Outcomes in Type 2 Diabetes.  N Engl J Med 2015; 372:2197-2206June 4, 2015DOI: 10.1056/NEJMoa1414266.

O'Donoghue ML, Braunwald E, White HD, et al. TIMI 52 investigators (S Goldman).  (2014) Effect of darapladib on major coronary events after an acute coronary syndrome: The SOLID-TIMI 52 randomized clinical trial. JAMA 2014; DOI:10.1001/jama. 2014.11061.

Lancaster JJ, Arnce SA, Johnson NM, Juneman E, Thai H, Kellar R, Vitorin JE, Burt J, Gaballa MA, Bahl JJ, Goldman S.  2014) An electrically coupled tissue-engineered cardiomyocyte scaffold improves cardiac function in rats with chronic heart failure.  Journal of Heart and Lung Transplantation 33:438-445.  http://dx.doi.org/10.1016/j.healun.2013.12.004

 

 

 

 

 

Patents: 

US Patent No: 6,534,676 B2 UA #03-075 Method to treat chronic heart failure and/or elevated cholesterol with thyroid analog (DITPA) issued 3/18/03, expiration date 5/12/21.  

US Patent No: 2002243801 Method to Treat Chronic Heart Failure and/or Elevated Cholesterol Levels using 3,5-Diiodothyropropionic Acid and Method to Prepare Same, Mexico issued 5/2/06, Australia issued 3/22/07, Canada issued 5/14/2011 

US Patent No: 7,504,435. Method for Stimulating Weight Loss and/or for Lowering Triglycerides in Patients issued 3/17/09, expiration date 4/13/2025. 

US Patent No: 8,399,518.  Administration of 3,5-Diiodothyroproprionic Acid for Stimulating Weight Loss, and/or Lowering Triglyceride Levels, and/or Treatment of Metabolic Syndrome issued March 19, 2013, expiration date 9/3/2031. 

Seeding and Co-Culture of a 3 Dimensional Fibroblast Construct (3DFC): UA/VA, UA09-061-US provisional patent serial number 61/212,280 and PCT patent application PCT/US10/30579. ssued March 2015.   

Lancaster JJ, Goldman S. (2105) Muscle cell patches and uses therefore US Provisional Application Serial No. 61/888882; UA13-144 filed 10-9-13. 

Advanced Research Distinction Track (RDT): 

 Pablo Sanchez (RDT 2015): "iPSC-Derived Cardiomyocycte Scaffold on Diastolic Function in Rats with Chronic Heart Failure" 

NIH High School Student Research Program: 

 Maria Mosqueda, Harvest Prep Academy, 2015

Monday, August 14, 2017